Mode
Text Size
Log in / Sign up
N/A N=21 Randomized Double-blind Supportive Care

Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye

Dry Eye · Dry Eye Syndromes

Enrolled (actual)
21
Serious AEs
0.0%
Results posted
Jan 2020
Primary outcome: Primary: Ocular Surface Tear Breakup Time — 3.81; 2.91 seconds — p=<0.01

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Scleral lenses treated with Tangible Hydra-PEG (Device); Untreated scleral lenses (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Tangible Science
Primary completion
Jan 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Ocular Surface Tear Breakup Time
3.81; 2.91 <0.01 sig
PRIMARY
Corneal Fluorescein Staining
0.92; 1.40 <0.05 sig
PRIMARY
Ocular Surface Disease Index (OSDI) Questionnaire
28.24; 35.10 <0.01 sig
PRIMARY
Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)
11.89; 17.30 <0.01 sig
SECONDARY
Tear Breakup Time Over the Surface of the Scleral Lens
5.88; 4.75 >0.05
SECONDARY
Lid Wiper Epitheliopathy
0.89; 1.41 <0.05 sig
SECONDARY
Contact Lens-related Papillary Conjunctivitis
0.89; 1.45 <0.01 sig
SECONDARY
Temporal Conjunctival Lissamine Green Staining
0.95; 1.23 <0.05 sig
SECONDARY
Nasal Conjunctival Lissamine Green Staining
0.79; 1.03 >0.05

Summary

Tangible Hydra-PEG is a novel coating technology designed to improve lens wettability, deposit resistance, and tear film breakup time. This is a randomized double masked cross-over study to examine contact lens discomfort and dry eye symptoms with Tangible Hydra-PEG treated scleral lens wear compared to untreated scleral lens wear in the dry eye patient population.

Eligibility Criteria

Inclusion Criteria

  • Reduced tear film break up time (TBUT), a sign of dry eye disease and contact lens discomfort
  • Scleral lens wearer (at least 8 hours per day for at least 5 days per week and have had their habitual lenses no longer than 1 year). Scleral lenses wear will be defined as 15.00 mm to 19.00 mm inclusive.

Exclusion Criteria

  • Disorders that affect sensitivity (herpetic disease, severe diabetes mellitus)
  • Anatomic variations of the conjunctiva that can impair proper scleral lens fitting
  • Pregnancy
  • Best corrected Snellen visual acuity worse than 20/30 in either eye
  • Ocular pathology other than dry eye (e.g. glaucoma, macular degeneration, keratoconus) which may significantly impact visual function.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03417505). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search